Development of second generation peptides modulating cellular adiponectin receptor responses

Frontiers in Chemistry

Volumn 2, Issue OCT, 2014, Pages

  Otvos, Laszlo ^a   Knappe, Daniel ^b   Hoffmann, Ralf ^b   Kovalszky, Ilona ^c   Olah, Julia ^c   Hewitson, Tim D ^d   Stawikowska, Roma ^e   Stawikowski, Maciej ^e   Cudic, Predrag ^e   Lin, Feng ^d   Wade, John D ^d   Surmacz, Eva ^f   Lovas, Sandor ^g  

^a Temple University   (United States)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^f TEMPLE UNIVERSITY   (United States)

^g CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiproliferation; Biodistribution; Dimeric peptide; Molecular dynamics simulations; Nanomolar activity

Indexed keywords

EID: 84934939255     PISSN: None     EISSN: 22962646     Source Type: Journal    
DOI: 10.3389/fchem.2014.00093     Document Type: Article

References (72)

1. Aggarwal, S., Singh, P., Topaloglu, O., Isaacs, J. T., and Denmeade, S. R. (2006). A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 66, 9171-9177. doi: 10.1158/0008-5472.CAN-06-1520
2. Almabuada, F., Diaz-Ruiz, A., Rabanal-Ruiz, Y., Peinado, J. R., Vazquez-Martinez, R., and Malagon, M. M. (2013). Adiponectin receptors form homomers and heteromers exhibiting distinct ligand binding and intracellular signaling properties. J. Biol. Chem. 288, 3112-3125. doi: 10.1016/j.ygcen.2011.08.017
3. Andricioaei, I., and Karplus, M. (2001). On the calculation of entropy from covariance matrices of the atomic fluctuations. J. Chem. Phys. 115, 6289-6292. doi: 10.1063/1.1401821
4. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., et al. (1999). Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79-83. doi: 10.1006/bbrc.1999.0255
5. Barb, D., Williams, C. J., Neuwirth, A. K., and Mantzoros, C. S. (2007). Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am. J. Clin. Nutr. 86, s858-s866.
6. Beauchamp, K. A., Lin, Y., Das, R., and Pande, V. S. (2012). Are protein force fields getting better? A systematic benchmark on 524 diverse NMR measurements. J. Chem. Theory Comput. 8, 1409-1414. doi: 10.1021/ct2007814
7. Beccari, S., Kovalszky, I., Wade, J. D., Otvos, L. Jr., and Surmacz, E. (2013). Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity. Peptides 44, 127-134. doi: 10.1016/j.peptides.2013.03.027
8. Beige, J., Heipmann, K., Stumvoll, M., Korner, A., and Kratzcsh, J. (2009). Paradoxical role for adiponectin in chronic renal diseases? An example of reverse pharmacology. Expert Opin. Ther. Targets 13, 163-173. doi: 10.1517/14728220802658481
9. Cai, X. J., Chen, L., Li, L., Feng, M., Li, X., Zhang, K., et al. (2010). Adiponectin inhibits liposaccahride-induced adventitial fibroblast migration and transition to myofibroblasts via AdipoR1-AMPK-iNOS pathway. Mol. Endocrinol. 24, 218-228. doi: 10.1210/me.2009-0128
10. Chiarugi, P., and Fiaschi, T. (2010). Adiponectin in health and diseases: from metabolic syndrome to tissue regeneration. Expert Opin. Ther. Targets 14, 193-206. doi: 10.1517/14728220903530712
11. Cudic, M., Condie, B. A., Weiner, D. J., Lysenko, E. S., Xiang, Z. Q., Insug, O., et al. (2002). Development of novel antibacterial peptides that kill resistant isolates. Peptides 23, 2071-2083. doi: 10.1016/S0196-9781(02)00244-9
12. Dadson, K., Liu, Y., and Sweeney, G. (2011). Adiponectin action: a combination of endocrine and autocrine/paracrine effects. Front. Endocrinol. 2:62. doi: 10.3389/fendo.2011.00062
13. Darden, T., York, D., and Pedersen, L. J. (1993). Particle mesh Ewald: an N· log(N) method for Ewald sums in large systems. Chem. Phys. 98, 10089-10092.
14. Ebina, K., Fukuhara, A., Ando, W., Hirao, M., Koga, T., Oshima, K., et al. (2009). Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin. Rheumatol. 28, 445-451. doi: 10.1007/s10067-008-1074-y
15. Fang, X., and Sweeney, G. (2006). Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem. Soc. Trans. 34, 798-801. doi: 10.1042/BST0340798
16. Fuerst, M., Taylor, C. G., Wright, B., Tworek, L., and Zahradka, P. (2012). Inhibition of smooth muscle cell proliferation by adiponectin requires proteolytic conversion to its globular form. J. Endocrinol. 215, 107-117. doi: 10.1530/JOE-12-0021
17. Gaelekman, O., Guseva, N., Hartigan, C., Apotheker, S., Gorgoglione, M., Gurav, K., et al. (2011). Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation 123, 186-194. doi: 10.1161/CIRCULATIONAHA.110.970145
18. Galic, S., Oakhill, J. S., and Steinberg, G. R. (2010). Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol. 316, 129-139. doi: 10.1016/j.mce.2009.08.018
19. Gonzalez-Angulo, A. M., and Meric-Bernstam, F. (2010). Metformin: a therapeutic opportunity in breast cancer. Clin. Cancer Res. 16, 1695-1700. doi: 10.1158/1078-0432.CCR-09-1805
20. Grubisic, S., Brancato, G., Pedone, A., and Barone, V. (2012). Extension of the AMBER force field to cyclic a, a dialkylated peptides. Phys. Chem. Chem. Phys. 14, 15308-15320. doi: 10.1039/c2cp42713c
21. Hadad, S. M., Fleming, S., and Thompson, A. M. (2008). Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit. Rev. Oncol. Hematol. 67, 1-7. doi: 10.1016/j.critrevonc.2008.01.007
22. Hess, B., Bekker, H., Berendsen, H. J. C., and Fraaije, J. G. E. M. (1997). LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463-1472.
23. Hess, B., Kutzner, C., Van Der Spoel, D., and Lindahl, E. (2008). GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4, 435-447. doi: 10.1021/ct700301q
24. Hewitson, T. D., Kelynack, K. J., Tait, M., Martic, M., Jones, C. L., Margolin, S. B., et al. (2001). Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J. Nephrol. 14, 453-460.
25. Janssen, M., Oyen, W. J., Dijkgraaf, I., Massuger, L. F., Frielink, C., Edwards, D. S., et al. (2002). Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 62, 6146-6151.
26. Jarde, T., Caldefie-Chezet, F., Goncalves-Mendes, N., Mishellany, F., Buechler, C., Penault-Llorca, F., et al. (2009). Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr. Relat. Cancer 16, 1197-1210. doi: 10.1677/ERC-09-0043
27. Jiang, W., Zhu, Z., and Thompson, H. J. (2008). Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res. 68, 5492-5499. doi: 10.1158/0008-5472.CAN-07-6721
28. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935. doi: 10.1063/1.445869
29. Kadowaki, T., and Yamauchi, T. (2011). Adiponectin receptor signaling: a new layer to the current model. Cell Metab. 13, 123-124. doi: 10.1016/j.cmet.2011.01.012
30. Kang, E. H., Lee, Y. J., Kim, T. K., Chang, C. B., Chung, J. H., Shin, K., et al. (2010). Adiponectin is a potential catabolic mediator in osteoarthritis cartilage. Arthritis Res. Ther. 12, R231. doi: 10.1186/ar3218
31. Karamifar, H., Habibian, N., Amirhakimi, G., Karamizadeh, Z., and Alipour, A. (2013). Adiponectin is a good marker for metabolic state among type 1 diabetes mellitus patients. Iran. J. Pediatr. 23, 295-301.
32. Klootwijk, W., Sleddens-Linkels, E., de Boer, R., Jansen, C. A., Autar, R., de Herder, W. W., et al. (1997). Renal clearance of the thyrotropin-releasing hormone-like peptide pyroglutamyl-glutamyl-prolineamide in humans. J. Clin. Endocrinol. Metab. 82, 3068-3073. doi: 10.1210/jcem.82.9.4219
33. Knappe, D., Otvos, L. Jr., De Pascali, F., Cassone, M., Scolaro, L., Abbadessa, G., et al. (2008). Drug development-targeted screening of leptin agonist glycopeptides. Int. J. Pept. Res. Ther. 14, 247-254. doi: 10.1007/s10989-008-9139-y
34. Knappe, D., Zahn, M., Sauer, U., Schiffer, G., Strater, N., and Hoffmann, R. (2011). Rational design of oncocin derivatives with superior protease stabilities and antibacterial activities based on the high-resolution structure of the oncocin-DnaK complex. Chembiochem 12, 874-876. doi: 10.1002/cbic.201000792
35. Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., et al. (2007). Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. U.S.A. 104, 937-942. doi: 10.1073/pnas.0605701104
36. Kovalszky, I., Surmacz, E., Scolaro, L., Cassone, M., Sztodola, A., Olah, J., et al. (2010). Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models. Diabetes Obes. Metab. 12, 393-402. doi: 10.1111/j.1463-1326.2009.01170.x
37. Kumar, P., Smith, T., Rahman, K., Mells, J. E., Thorn, N. E., Saxena, N. K., et al. (2014). Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis. FASEB J. doi: 10.1096/fj.14-253229. [Epub ahead of print].
38. Li, D., and Bruschweiler, R. (2010). NMR-based protein potentials. Angew. Chem. Int. Ed Engl. 49, 6778-6780. doi: 10.1002/anie.201001898
39. Lin, T., Qiu, Y., Liu, Y., Mohan, R., Li, Q., and Lei, B. (2013). Expression of adiponectin and its receptors in type 1 diabetes mellitus in human and mouse retinas. Mol. Vis. 19, 1769-1778.
40. Miller, R. A., Chu, Q., Le Lay, J., Scherer, P. E., Ahima, R. S., Kaestner, K. H., et al. (2011). Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J. Clin. Invest. 212, 2518-2528. doi: 10.1172/JCI45942
41. Mu, Y., Nguyen, P. H., and Stock, G. (2005). Energy landscape of a small peptide revealed by dihedral angle principal component analysis. Proteins 58, 45-52. doi: 10.1002/prot.20310
42. Noto, P. B., Abbadessa, G., Cassone, M., Mateo, G. D., Agelan, A., Wade, J. D., et al. (2008). Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci. 17, 1249-1255. doi: 10.1110/ps.034330.108
43. Obeid, S., and Hebbard, L. (2012). Role of adiponectin and its receptors in cancer. Cancer Biol. Med. 9, 213-220. doi: 10.7497/j.issn.2095-3941.2012.04.001
44. Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K. I., Matsuda, K., et al. (2013). A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503, 493-499. doi: 10.1038/nature12656
45. Otvos, L. Jr., Haspinger, E., La Russa, F., Maspero, F., Graziano, P., Kovalszky, I., et al. (2011a). Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 11:90. doi: 10.1186/1472-6750-11-90
46. Otvos, L. Jr., Kovalszky, I., Riolfi, M., Ferla, R., Olah, J., Sztodola, A., et al. (2011c). Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur. J. Cancer 47, 1578-1584. doi: 10.1016/j.ejca.2011.01.018
47. Otvos, L. Jr., Kovalszky, I., Scolaro, L., Sztodola, A., Olah, J., Cassone, M., et al. (2011b). Peptide-based receptor antagonists for cancer treatment and appetite regulation. Biopolymers 96, 117-125. doi: 10.1002/bip.21377
48. Otvos, L. Jr., and Surmacz, E. (2011). Targeting the leptin receptor: a potential new mode of treatment for breast cancer. Expert Rev. Anticancer Ther. 11, 1147-1150. doi: 10.1586/era.11.109
49. Otvos, L. Jr., Terrasi, M., Cascio, S., Cassone, M., Abbadessa, G., De Pascali, F., et al. (2008). Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochim. Biophys. Acta 1783, 1745-1754. doi: 10.1016/j.bbamcr.2008.05.007
50. Otvos, L. Jr., Vetter, S. W., Koladia, M., Knappe, D., Schmidt, R., Ostorhazi, E., et al. (2014). The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor. Amino Acids 46, 873-882. doi: 10.1007/s00726-013-1650-6
51. Ozturk, K., Avcu, F., and Ural, A. U. (2012). Aberrant expressions of leptin and adiponectin receptor isoforms in chronic myeloid leukemia patients. Cytokine 57, 61-67. doi: 10.1016/j.cyto.2011.10.004
52. Patriksson, A., and Van der Spoel, D. (2008). A temperature predictor for parallel tempering simulations. Phys. Chem. Chem. Phys. 10, 2073-2077. doi: 10.1039/b716554d
53. Pepping, J. K., Otvos, L. Jr., Surmacz, E., Gupta, S., Keller, J. N., and Bruce-Keller, A. J. (2014). Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitors. J. Neuroimmune Pharmacol. 9, 388-398. doi: 10.1007/s11481-014-9529-1
54. Potter, J. J., and Mezey, E. (2007). Acetaldehyde increases endogenous adiponectin and fibrogenesis in hepatic stellate cells but exogenous adiponectin inhibits fibrogenesis. Alcohol. Clin. Exp. Res. 31, 2092-2100. doi: 10.1111/j.1530-0277.2007.00529.x
55. Powell, M. F., Stewart, T., Otvos, L. Jr., Urge, L., Gaeta, F., Sette, A., et al. (1993). Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation peptide reactivity in human serum. Pharmacol. Res. 10, 1268-1273. doi: 10.1023/A:1018953309913
56. R Core Team R (2013). A Language and Environment for Statistical computing, R Foundation for Statistical Computing: Vienna, Austria. Available online at: http://www.R-project.org/.
57. Rodemann, H. P., and Muller, G. A. (1990). Abnormal growth and clonal proliferation of fibroblasts derived from kidneys with interstitial fibrosis. Proc. Soc. Exp. Biol. Med. 195, 57-63. doi: 10.3181/00379727-195-43118
58. Rozgonyi, F., Szabo, D., Kocsis, B., Ostorhazi, E., Abbadessa, G., Cassone, M., et al. (2009). The antibacterial effect of a proline-rich antibacterial peptide A3-APO. Curr. Med. Chem. 16, 3996-4002. doi: 10.2174/092986709789352295
59. Rutkowski, J. M., Davis, K. E., and Scherer, P. E. (2009). Mechanisms of obesity and related pathologies: the macro-and microcirculation of adipose tissue. FEBS J. 276, 5738-5746. doi: 10.1111/j.1742-4658.2009.07303.x
60. Rutkowski, J. M., Wang, Z. V., Park, A. S., Zhang, J., Zhang, D., Hu, M. C., et al. (2013). Adiponectin promotes functional recovery after podocyte ablation. J. Am. Soc. Nephrol. 24, 268-282. doi: 10.1681/ASN.2012040414
61. Ryan, A. S., Berman, D. M., Nicklas, B. J., Sinha, M., Gingerich, R. L., Meneilly, G. S., et al. (2003). Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 26, 2383-2388. doi: 10.2337/diacare.26.8.2383
62. Schaffler, A., Scholmerich, J., and Buechler, C. (2007). Mechanisms of disease: adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat. Clin. Pract. Endocrinol. Metab. 3, 345-354. doi: 10.1038/ncpendmet0456
63. Sugita, Y., and Okamoto, Y. (1999). Replica-exchange molecular dynamics method for protein folding. Chem. Phys. Lett. 314, 141-151. doi: 10.1016/S0009-2614(99)01123-9
64. Sun, Y., Zang, Z., Zhong, L., Wu, M., Su, Q., Gao, X., et al. (2013). Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS ONE 8:e63354. doi: 10.1371/journal.pone.0063354
65. Tian, S. S., Lamb, P., King, A. G., Miller, S. G., Kessler, L., Luengo, J. I., et al. (1998). A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science 281, 257-259. doi: 10.1126/science.281.5374.257
66. Wijesekara, N., Krishnamurthy, M., Bhattacharjee, A., Suhail, A., Sweeney, G., and Wheeler, M. B. (2010). Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic ß-cell apoptosis and increases insulin gene expression and secretion. J. Biol. Chem. 285, 33623-33631. doi: 10.1074/jbc.M109.085084
67. Wintrob, Z. A. P., Radpasand, H., Elmeshad, M. H., Barima, A., Rabey, J. L., Chmiel, K. A., et al. (2013). Adiponectin receptor mediated weight regulation: an inflammation-independent mechanism? FASEB J. 27, 1123.13. doi: 10.1096/fj.1530-6860
68. Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., et al. (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769. doi: 10.1038/nature01705
69. Yang, J., Lin, S. C., Chen, G., He, L., Hu, Z., Chan, L., et al. (2013). Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. J. Am. Soc. Nephrol. 24, 1644-1659. doi: 10.1681/ASN.2013030217
70. Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama, A., Ouchi, N., et al. (2000). Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelonomonocytic progenitors and the function of macrophages. Blood 96, 1723-1732.
71. Zhou, L., Liu, S. P., Chen, L. Y., Li, J., Ong, L. B., Guo, L., et al. (2011). The structural parameters for antimicrobial activity, human epithelial cell cytotoxicity and killing mechanism of synthetic monomer and dimer analogues derived from hBD3 C-terminal region. Amino Acids 40, 123-133. doi: 10.1007/s00726-010-0565-8
72. Ziemke, F., and Mantzoros, C. S. (2010). Adiponectin in insulin resistance: lessons from translational research. Am. J. Clin. Nutr. 91, 258S-261S. doi: 10.3945/ajcn.2009.28449C